Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Mulligan

Showing results (241-250 of 245) with videos related to

Pageof 25
Sort By:
You have reached the last page of results.This site can display upto 245 results.
ACS Central Science|October 3, 2022
Correction to "An Iterative Approach Guides Discovery of the FabI Inhibitor Fabimycin, a Late-Stage Antibiotic Candidate with <i>In Vivo</i> Efficacy against Drug-Resistant Gram-Negative Infections"Erica N Parker, Brett N Cain, Behnoush Hajian, et al.
Leukemia|June 9, 2017
Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLLJ R Brown, P Hillmen, S O'Brien, et al.
Blood Advances|January 25, 2023
BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinibSilvia Bonfiglio, Lesley-Ann Sutton, Viktor Ljungström, et al.
The New England Journal of Medicine|June 3, 2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemiaJohn C Byrd, Jennifer R Brown, Susan O'Brien, et al.
Journal of the American College of Cardiology|February 8, 2020
Global Longitudinal Strain and Cardiac Events in Patients With Immune Checkpoint Inhibitor-Related MyocarditisMagid Awadalla, Syed S Mahmood, John D Groarke, et al.
Pageof 25

Showing results (241-250 of 245) with videos related to

Sort By:
Pageof 25
You have reached the last page of results.This site can display upto 245 results.
ACS Central Science|October 3, 2022
Correction to "An Iterative Approach Guides Discovery of the FabI Inhibitor Fabimycin, a Late-Stage Antibiotic Candidate with <i>In Vivo</i> Efficacy against Drug-Resistant Gram-Negative Infections"Erica N Parker, Brett N Cain, Behnoush Hajian, et al.
Leukemia|June 9, 2017
Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLLJ R Brown, P Hillmen, S O'Brien, et al.
Blood Advances|January 25, 2023
BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinibSilvia Bonfiglio, Lesley-Ann Sutton, Viktor Ljungström, et al.
The New England Journal of Medicine|June 3, 2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemiaJohn C Byrd, Jennifer R Brown, Susan O'Brien, et al.
Journal of the American College of Cardiology|February 8, 2020
Global Longitudinal Strain and Cardiac Events in Patients With Immune Checkpoint Inhibitor-Related MyocarditisMagid Awadalla, Syed S Mahmood, John D Groarke, et al.
Pageof 25